

Successful ablation of large diameter Great Saphenous Vein with Varithena®

Patient History

- 57 year old female with CEAP C3 disease in her left leg for over 20 years after her second child (Figure 1). After symptoms continued to worsen with heaviness, swelling, tenderness, and hemorrhaging, she sought treatment. Patient has trialed compression therapy and leg elevation for at least 3 months. Patient has no other history of treatment for chronic venous insufficiency.
- Duplex Ultrasound of left Great Saphenous Vein (GSV): maximum diameter of 15 mm with 7.2 sec of reflux.

Treatment

- After venous mapping, access was gained above the knee with a 4F micro-introducer kit into the left GSV.
- During the Varithena® procedure, a total of 8 cc was administered. The foam was initially allowed to travel antegrade to the saphenofemoral junction (SFJ). Pressure was applied at the SFJ when the foam column arrived within 3 cm and was held until appropriate venospasm was noted. The foam was then allowed to flow retrograde for below the knee ablation.
- During the procedure, patient was placed in steep Trendelenburg position. Ultrasound was utilized throughout the procedure to identify sites for injection and to monitor for response to Varithena®.

Results

- Immediately after treatment, closure was observed under ultrasound and visually.
- Patient complied with post-procedure care instructions for both treatments: daily compression stockings, full wraps for 48 hours, and daily walking.
- Patient had complete resolution in symptoms and is still symptom-free at 6 week follow up (Figure 3).

Conclusion

- Varithena® resulted in both a clinical and visual improvement following the first treatment in GSV with a maximum diameter of 15mm.
- Both patient and provider were extremely satisfied in her outcomes.
- Varithena® is a viable and successful treatment option for patients who have large truncal veins.



Figure 1. Pre-treatment medial view of left visible varicosities.




Figure 3. Post-treatment medial view of the left calf at 6 weeks.

"The result was dramatic both clinically, with symptom resolution, and aesthetically."

Frank Navetta, MD, FACC, FSCAI

Practice: Tyler Cardiovascular Consultants, P.A.

Certifications: Board-Certified in Interventional Cardiology, Cardiovascular Disease, and Internal Medicine.



INDICATIONS

Varithena® (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

IMPORTANT SAFETY INFORMATION

The use of Varithena® is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease.

Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately.

Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.

Varithena® can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis.

The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.

Physicians administering Varithena® must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena®.

See Full Prescribing Information for Varithena®.



© 2017 Biocompatibles, Inc., a BTG International group company
All rights reserved NA-VAR-2017-0000
Varithena is a registered trademark and is a trademark of Provensis Ltd,
a BTG International group company
BTG and the BTG roundel logo are registered trademarks of BTG International Ltd

Varithena®
(polidocanol injectable foam) 1%